Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SGP vs BMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BMY Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 10–0 Matrix Metrics)

BMY Overall Winner 6-Pillar Tally: SGP 0 – 6 BMY Matrix Metrics: SGP 0 – 10 BMY

As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGP carries a Unified Composite Score of 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin), whereas BMY carries 53.5/100 (HOLD) at $62.93 (9.4x Forward P/E, 32.4% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGP vs BMY
SGP US Equity
SGP
Institutional Equity
$32.24
-1.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.38β · 70% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 15.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.9% over 20 days), RSI 53
RSI-14: 52.7 · SMA20: $32.43 · SMA50: $28.85
BMY NYSE Head-to-Head Winner
Bristol-Myers Squibb Co.
Pharmaceutical Preparations
$62.93
-0.79% 1D
Market Cap $129.7B
TTM Revenue $50.0B
Forward P/E 9.4x
Beta / 30D Vol 0.17β · 31% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 50.0 Fund 58.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.5 · SMA20: $62.28 · SMA50: $61.82

6-Pillar Scorecard Institutional Category Breakdown (SGP 0 – 6 BMY)

Columns: Metric · SGP · BMY
1. Valuation Multiples BMY
Forward P/E N/M 9.4x
Trailing P/E N/M 14.1x
PEG Ratio N/M 17.39x
EV / Revenue N/M 3.3x
2. Growth & Scale BMY
Revenue Growth (YoY) N/A +6.9%
Earnings Growth (YoY) N/A -2.8%
TTM Revenue (USD) N/A $50.0B
Market Cap N/A $129.7B
3. Profitability & Quality BMY
Gross Margin N/A 70.5%
Operating Margin N/A 32.4%
Net Profit Margin N/A 18.5%
Return on Equity (ROE) N/A 44.0%
4. Balance Sheet & Cash Flow BMY
Cash Generation (TTM) N/A $9.29B
Cash Flow Margin N/A 18.6%
Net Cash / Leverage N/A ROE $35.2B Net Debt (1.91x D/E)
Dividend Yield None (0.00%) 4.04%
5. Options & Positioning BMY
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 45.6% (31st %ile)
Put/Call OI Skew N/A 1.21x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BMY
OpEx & R&D Intensity N/A 38.1% of Rev ($19.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Institutional Equity Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGP (0) vs BMY (10)
Institutional Metric SGP BMY Criterion Row Edge
Market Capitalization
Scale
N/A $129.7B Larger Scale BMY
Trailing P/E Ratio
Valuation
N/M 14.1x Lower Multiple BMY
Forward P/E Ratio
Valuation
N/M 9.4x Lower Multiple BMY
Revenue Growth (YoY)
Growth
N/A +6.9% Higher Growth BMY
Operating Margin (TTM)
Profitability
N/A 32.4% Higher Margin BMY
Net Profit Margin
Profitability
N/A 18.5% Higher Margin BMY
Return on Equity (ROE)
Capital Efficiency
N/A 44.0% Higher ROE BMY
52-Week Range Position
Momentum
66% ($17–$40) 76% ($45–$69) Stronger Trend BMY
Beta / 30D Volatility
Risk Regime
1.38β · 70% Vol 0.17β · 31% Vol Lower Realized Risk BMY
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 53.5 / 100 (HOLD) Higher Composite BMY
Trailing 12M Revenue (USD)
Operating Scale
N/A $50.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 70.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 17.39x PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $9.29B ($35.2B Net Debt (1.91x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGP +29.01 pp
SGP: +34.33% · BMY: +5.32%
3M Horizon SGP +29.49 pp
SGP: +24.77% · BMY: -4.72%
6M Horizon SGP +35.15 pp
SGP: +44.96% · BMY: +9.81%
1Y Horizon SGP +20.6 pp
SGP: +22.12% · BMY: +1.52%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SGP vs BMY. Trailing 12-month operating profitability (SGP N/A vs BMY 32.4%) and valuation multiples (SGP N/M vs BMY 9.4x Forward P/E) are benchmarked directly in Pillar 4 below.

SGP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$50.0B
Gross Margin70.5%
Op. Margin32.4%
ROE / Fwd P/E44.0% · 9.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMY CONSOLIDATION
51d in phase · OBV NEUTRAL
Current IV 45.6%
IV Percentile 31st %ile
Put/Call OI Skew 1.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $62.93 · IV 34.2%

BMY Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($6,293)

Compare $6,293 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 34.2% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $62.5 / $67.5 Bull Call Spread

Buy 1x $62.5C · Sell 1x $67.5C · 31d

Net Entry $197 Debit
T+5d @ +5% Move +$100 (+51%)
Max Risk / Buffer $197 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $57.5 Bull Put Spread

Sell 1x $60P · Buy 1x $57.5P · 31d

Net Entry $61 Credit
Max Credit / Yield +$61 (+32.3% RoM)
Max Risk / Buffer -5.6% Cushion ($189 Mgn)
5d Edge & Liquidity 71% PoP · Liq A
Simulate 5-Day Payoff →
5-DAY DOWNSIDE SPREAD Liq A

Dec 18 $65 / $60 Bear Put Spread

Buy 1x $65P · Sell 1x $60P · 31d

Net Entry $211 Debit
T+5d @ -5% Drop +$111 (+53%)
Max Risk / Buffer $211 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMY Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $129.7B market capitalization and 32.4% operating margin.
OpEx & R&D Reinvestment 38.1% of Rev ($19.1B)
90D Engineering Disclosures 0 Published

Investor FAQ SGP vs BMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Bristol-Myers Squibb Co. (BMY) is the stronger overall head-to-head candidate over SGP (SGP) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SGP carries a Unified Composite Score of 39.3/100 (SELL) at $32.24 (N/M Forward P/E, N/A operating margin), whereas BMY carries 53.5/100 (HOLD) at $62.93 (9.4x Forward P/E, 32.4% operating margin). Technically, SGP sits in a Markup phase (RSI 52.7, UNCLASSIFIED options structure) and BMY sits in a Neutral phase (RSI 53.5, CONSOLIDATION options structure).

BMY leads the Growth & Scale pillar: SGP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BMY at +6.9% YoY revenue growth and -2.8% YoY earnings growth on $50.0B TTM revenue (70.5% gross margin, 32.4% operating margin). On trailing 12-month operating scale, SGP generates N/A in USD-normalized revenue versus $50.0B for BMY. In operating R&D and SG&A reinvestment, SGP deploys N/A (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($19.1B) (0 disclosures) for BMY.

BMY screens cheaper on headline valuation multiples. SGP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BMY trades at 9.4x Forward P/E, 14.1x Trailing P/E, 17.39x PEG, and 3.3x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGP (N/A ROE) versus BMY (44.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SGP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.38β · 70% Vol realized risk). By comparison, BMY carries 45.6% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 1.21x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.17β · 31% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.